GlassScriptPhysician profile
Robert Cameron Hendry
NPI 1437723913
$1,804.01
in general payments reported to CMS, 2019-2025
14 companies · $742 in 2025
The $742 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.68 · 2022: $124 · 2023: $203 · 2024: $691 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $347.12 | 2023-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $273.12 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $248.82 | 2024-2025 | Fasenra, Tezspire |
| Genzyme Corporation | $149.94 | 2025 | |
| Medtronic, INC. | $132.05 | 2024 | Intellis Adaptivestim |
| Actelion Pharmaceuticals US, INC. | $124.41 | 2024 | Opsumit, Uptravi |
| Abbvie INC. | $124.17 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $122.06 | 2023 | Eliquis |
| Olympus America INC. | $103.41 | 2024 | Spiration Valve System |
| Pulmonx Corporation | $56.15 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Pfizer INC. | $48.73 | 2023-2024 | |
| Shionogi INC | $29.35 | 2023 | Fetroja |
| Convatec INC. | $23.61 | 2021 | |
| Integra Lifesciences Corporation | $21.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hendry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.